Cellestial Health

Cellestial Health is a preclinical biopharmaceutical company that spun out of the University of Cambridge in 2023 to develop novel therapies for Parkinson’s disease and other neurological conditions. The company focuses on targeting astrocytic networks, a crucial component of brain health that has traditionally been overlooked in drug development. By utilizing brain-permeable small molecules and peptides, the company aims to restore astrocytic function, reduce toxic inflammation, and prevent the accumulation of harmful proteins to halt disease progression rather than merely managing symptoms. Its platform validates molecular targets to build a pipeline of therapeutics, supported by collaborations with academic institutions such as the University of Cambridge and the University of Manchester, as well as partnerships with preclinical research organizations like Charles River Laboratories.

The company’s work addresses the significant global unmet need for disease-modifying treatments for neurodegenerative disorders. By focusing on the root causes of neuronal damage through astrocyte modulation, Cellestial Health seeks to provide meaningful improvements in patient quality of life. The firm has secured substantial pre-seed and seed funding from investors including Zinc VC and ET Capital, alongside early-stage grants from organizations such as Parkinson’s UK and Cambridge Enterprise. This capital is being directed toward the preclinical development of its lead drug candidates as the company works toward future clinical translation. Given the shared underlying mechanisms of inflammation and cell stress in various brain conditions, the company’s technology platform also offers potential for future expansion into therapies for other disorders such as multiple sclerosis, stroke, and depression.